Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2021 – Myelofibrosis: Wrap-up
ASH 2021 – Myelofibrosis: Wrap-up
AVID200 Improves Platelet Counts in Patients with Myelofibrosis After Discontinuation of Ruxolitinib
ASH 2021 – Myelofibrosis: Wrap-up
Previous studies have established a role for TGFβ in promoting development and progression of myelofibrosis. Evidence suggests AVID200, a TGFβ1/3 inhibitor, may modulate TGFβ signaling mechanisms associated with myelofibrosis.
Read More ›
Fedratinib Improves Overall and Landmark Survival Rates in Patients Diagnosed with Myelofibrosis and Prior Ruxolitinib Treatment
ASH 2021 – Myelofibrosis: Wrap-up
Fedratinib, a JAK2 inhibitor, was recently approved to treat myelofibrosis in patients previously treated with ruxolitinib. Evidence suggests fedratinib may be a viable therapeutic option to improve survival in this patient population.
Read More ›
Quality Improvement Program Identifies Disparities and Opportunities to Improve Delivery of Patient-Centered Care in Patients with Myeloproliferative Neoplasms
ASH 2021 – Myelofibrosis: Wrap-up
The rate of thrombus formation in patients with myelofibrosis is not well-defined. The intersection of IPSS score and JAK mutation may reliably indicate risk of vascular events in these patients.
Read More ›
Pelabresib Monotherapy Demonstrates Clinical Activity in a Subset of Patients with Myelofibrosis with Limited Treatment Options and Poor Outcomes
ASH 2021 – Myelofibrosis: Wrap-up
Patients with myelofibrosis who are intolerant, refractory to, or ineligible for JAK inhibitor therapy such as ruxolitinib are generally difficult to treat and have poor prognoses. Evidence suggests pelabresib can safely and effectively improve clinical outcomes in this patient subset.
Read More ›
Earlier Initiation of Fedratinib May Improve Clinical Profile in Patients with Myelofibrosis Previously Treated with Ruxolitinib
ASH 2021 – Myelofibrosis: Wrap-up
For patients with myelofibrosis, fedratinib has emerged as another option for first-line therapy after prior ruxolitinib therapy. In a real-world setting, data indicate earlier initiation of fedratinib may be of clinical benefit in this patient population.
Read More ›
Parsaclisib May Be an Effective Therapeutic Option for Patients Diagnosed with Myelofibrosis with Low Platelet Count
ASH 2021 – Myelofibrosis: Wrap-up
Patients with a low platelet count represent a difficult-to-treat group because ruxolitinib treatment is typically first-line therapy for myelofibrosis and is associated with suboptimal or loss of response and thrombocytopenia. Parsaclisib may be an effective add-on option for this patient subgroup.
Read More ›
Potential Emergence of Recently Approved Fedratinib in the Myelofibrosis First-Line Treatment Landscape
ASH 2021 – Myelofibrosis: Wrap-up
FREEDOM2 is the first trial to compare fedratinib to best available therapies, including ruxolitinib and other JAK inhibitors, in patients with myelofibrosis who were previously treated with ruxolitinib for at least 3 months.
Read More ›
IPSS Score and JAK Mutation Status Together May Identify Myelofibrosis Patient Subgroups at Risk of Thrombosis
ASH 2021 – Myelofibrosis: Wrap-up
The rate of thrombus formation in patients with myelofibrosis is not well-defined. The intersection of IPSS score and
JAK
mutation may reliably indicate risk of vascular events in these patients.
Read More ›
Bomedemstat Improved Clinical Profile of Patients with Advanced Myelofibrosis
ASH 2021 – Myelofibrosis: Wrap-up
Patients with advanced myelofibrosis and heavy mutation burden have limited safe and effective therapeutic options. Preliminary clinical trial evidence indicates bomedemstat provides clinical benefit to patients in this population.
Read More ›
Results from FREEDOM Indicate Fedratinib Is Effective and Safe in Patients with Myelofibrosis Previously Treated with Ruxolitinib
ASH 2021 – Myelofibrosis: Wrap-up
Evidence suggests fedratinib, a selective JAK2 inhibitor, demonstrates safety and efficacy in patients with myelofibrosis previously treated with ruxolitinib with appropriate mitigation strategies.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us